158 related articles for article (PubMed ID: 38000171)
21. Highly aligned stromal collagen is a negative prognostic factor following pancreatic ductal adenocarcinoma resection.
Drifka CR; Loeffler AG; Mathewson K; Keikhosravi A; Eickhoff JC; Liu Y; Weber SM; Kao WJ; Eliceiri KW
Oncotarget; 2016 Nov; 7(46):76197-76213. PubMed ID: 27776346
[TBL] [Abstract][Full Text] [Related]
22. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.
Dosch AR; Dai X; Reyzer ML; Mehra S; Srinivasan S; Willobee BA; Kwon D; Kashikar N; Caprioli R; Merchant NB; Nagathihalli NS
Mol Cancer Res; 2020 Apr; 18(4):623-631. PubMed ID: 31949002
[TBL] [Abstract][Full Text] [Related]
23. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice.
Jiang SH; Li J; Dong FY; Yang JY; Liu DJ; Yang XM; Wang YH; Yang MW; Fu XL; Zhang XX; Li Q; Pang XF; Huo YM; Li J; Zhang JF; Lee HY; Lee SJ; Qin WX; Gu JR; Sun YW; Zhang ZG
Gastroenterology; 2017 Jul; 153(1):277-291.e19. PubMed ID: 28315323
[TBL] [Abstract][Full Text] [Related]
24. Orthotopic Models of Pancreatic Cancer to Study PDT.
Obaid G; Mai Z; Hasan T
Methods Mol Biol; 2022; 2451():163-173. PubMed ID: 35505017
[TBL] [Abstract][Full Text] [Related]
25. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Vogel A; Ciardiello F; Hubner RA; Blanc JF; Carrato A; Yang Y; Patel DA; Ektare V; de Jong FA; Gill S
Cancer Treat Rev; 2016 Nov; 50():142-147. PubMed ID: 27676174
[TBL] [Abstract][Full Text] [Related]
26. Tumor and stroma COL8A1 secretion induces autocrine and paracrine progression signaling in pancreatic ductal adenocarcinoma.
Yan B; Liu L; Zhao L; Hinz U; Luo Y; An X; Gladkich J; de la Torre C; Huang Z; Schrapel D; Gross W; Fortunato F; Schaefer M; Gaida MM; Herr I
Matrix Biol; 2022 Dec; 114():84-107. PubMed ID: 36375776
[TBL] [Abstract][Full Text] [Related]
27. Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives.
Woo W; Carey ET; Choi M
Onco Targets Ther; 2019; 12():1455-1463. PubMed ID: 30863113
[TBL] [Abstract][Full Text] [Related]
28. Protective Desmoplasia in Pancreatic Adenocarcinoma: High Vitamin D Receptor Expression and Collagen Content.
Bahat AV; Bar-David S; Brooks A; Aizic A; Greenberg O; Wolf I; Klausner JM; Lahat G; Nizri E
Anticancer Res; 2020 Nov; 40(11):6457-6464. PubMed ID: 33109584
[TBL] [Abstract][Full Text] [Related]
29. Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer.
Merz V; Zecchetto C; Santoro R; Simionato F; Sabbadini F; Mangiameli D; Piro G; Cavaliere A; Deiana M; Valenti MT; Bazan D; Fedele V; Lonardi S; Melisi D
Clin Cancer Res; 2020 Sep; 26(17):4661-4669. PubMed ID: 32532788
[TBL] [Abstract][Full Text] [Related]
30. Multimodal Targeted Nanoparticle-Based Delivery System for Pancreatic Tumor Imaging in Cellular and Animal Models.
Medina OP; Tower RJ; Medina TP; Ashkenani F; Appold L; Bötcher M; Huber L; Will O; Ling Q; Hauser C; Rohwedder A; Heneweer C; Peschke E; Hövener JB; Lüdtke-Buzug K; Boretius S; Mentlein R; Kairemo K; Glüer CC; Sebens S; Kalthoff H
Curr Pharm Des; 2022; 28(4):313-323. PubMed ID: 32679012
[TBL] [Abstract][Full Text] [Related]
31. First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer.
Taghizadeh H; Unseld M; Schmiderer A; Djanani A; Wilthoner K; Buchinger D; Prager GW
Cancer Chemother Pharmacol; 2020 Jul; 86(1):109-115. PubMed ID: 32556829
[TBL] [Abstract][Full Text] [Related]
32. Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model.
Wang J; Chan DKW; Sen A; Ma WW; Straubinger RM
Mol Cancer Ther; 2019 Nov; 18(11):2074-2084. PubMed ID: 31363010
[TBL] [Abstract][Full Text] [Related]
33. Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience.
Tossey JC; Reardon J; VanDeusen JB; Noonan AM; Porter K; Arango MJ
Med Oncol; 2019 Sep; 36(10):87. PubMed ID: 31494781
[TBL] [Abstract][Full Text] [Related]
34. Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI.
Erstad DJ; Sojoodi M; Taylor MS; Jordan VC; Farrar CT; Axtell AL; Rotile NJ; Jones C; Graham-O'Regan KA; Ferreira DS; Michelakos T; Kontos F; Chawla A; Li S; Ghoshal S; Chen YI; Arora G; Humblet V; Deshpande V; Qadan M; Bardeesy N; Ferrone CR; Lanuti M; Tanabe KK; Caravan P; Fuchs BC
Clin Cancer Res; 2020 Sep; 26(18):5007-5018. PubMed ID: 32611647
[TBL] [Abstract][Full Text] [Related]
35. Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.
Otsu T; Inokawa Y; Takami H; Hayashi M; Kurimoto K; Tanaka N; Tanaka H; Shimizu D; Hattori N; Kanda M; Tanaka C; Nakayama G; Kodera Y
Anticancer Res; 2022 Aug; 42(8):3889-3894. PubMed ID: 35896232
[TBL] [Abstract][Full Text] [Related]
36. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.
Bang YJ; Li CP; Lee KH; Chiu CF; Park JO; Shan YS; Kim JS; Chen JS; Shim HJ; Rau KM; Choi HJ; Oh DY; Belanger B; Chen LT
Cancer Sci; 2020 Feb; 111(2):513-527. PubMed ID: 31789476
[TBL] [Abstract][Full Text] [Related]
37. Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study.
Nagashima S; Kobayashi S; Tsunoda S; Yamachika Y; Tozuka Y; Fukushima T; Morimoto M; Ueno M; Furuse J; Maeda S
Int J Clin Oncol; 2024 Feb; 29(2):188-194. PubMed ID: 37991558
[TBL] [Abstract][Full Text] [Related]
38. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States.
Barzi A; Miksad R; Surinach A; Corvino FA; Wang S; Torres AZ; Mamlouk K; Pulgar S; Valderrama A; Bekaii-Saab T; Ahn D
Pancreas; 2020 Feb; 49(2):193-200. PubMed ID: 32011529
[TBL] [Abstract][Full Text] [Related]
39. Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs.
Milano G; Innocenti F; Minami H
Cancer Sci; 2022 Jul; 113(7):2224-2231. PubMed ID: 35445479
[TBL] [Abstract][Full Text] [Related]
40. Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages.
Incio J; Suboj P; Chin SM; Vardam-Kaur T; Liu H; Hato T; Babykutty S; Chen I; Deshpande V; Jain RK; Fukumura D
PLoS One; 2015; 10(12):e0141392. PubMed ID: 26641266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]